TargetRx to present PhaseⅠclinical data of TGRX-326 at the 2023 ASCO Annual Meeting

2023-05-05 Views:

TargetRx will present clinical data from PhaseⅠstudy of TGRX-326 in Advanced ALK-positive non-small cell lung cancer (NSCLC) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The conference will be held at McCormick Place in Chicago, Illionois from June 2-6, 2023.

Details of the poster presentation is as follows:



First-in-human, multicenter phaseⅠstudy of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer


Session Type: Poster Session


Abstract Presentation Number: 9113


Poster Session: Lung Cancer ---- Non-Small Cell Metastatic


Presenter: Hongyun Zhao, PhD| Department of Clinical Research, Sun Yat-sen University Cancer Center


Session Date and Time:

June 4, 2023, 8:00 AM-11:00 AM. CDT

About TGRX-326

TGRX-326 is a highly potent and selective third-generation anaplastic lymphoma kinase (ALK) tyrosine kinases inhibitor (TKI) for the treatment of patients with ALK-positive advanced NSCLC. It's been developed to address acquired resistance to earlier-generation ALK TKIs, with potency against a broad spectrum of ALK kinase-domain resistant mutations, including G1202R. TGRX-326 is currently in Phase I/II clinical trials for advanced ALK/ROS1 NSCLC.

Related Link: